Letter by Mitchell et al Regarding Article, "Urinary Prostaglandin Metabolites:
An Incomplete Reckoning and a Flush to Judgment"
To the Editor:
We would like to thank Dr Grosser et al 1 for their continued interest in our work. While we may not agree with their arguments or their opinions of our study, 2 we welcome debate in this extremely important area. We take this opportunity to address the points that they raise.
First, although urine may well be a convenient compartment within which to measure markers of prostacyclin and thromboxane A 2 , numerous observations, [3] [4] [5] [6] [7] [8] [9] [10] of which ours is only the latest, 2 indicate that they poorly reflect production within the circulation and the reactivities of endothelial cells and platelets.
Second, the literature that Grosser et al 1 cite is somewhat selective and in places inaccurate. For example, reference 3, 11 which the authors cite to substantiate the statement "Most insights into the in vivo biology and pharmacology of the prostaglandin pathway have derived from the measurement of metabolites, particularly in urine" refers to a paper published in 1975 which makes no references to prostacyclin, PGI-M (2,3-dinor-6-keto-PGF1α), thromboxane, or TX-M (11-dehydro-TXB2), being published before the discovery of prostacyclin. 12 Third, the studies selected to substantiate the point that "there is a striking discordance between the capacity of cells to make these lipids and their actual formation in vivo" referring to platelet thromboxane A 2 and urinary TXM, in fact, serve to corroborate the view that urinary prostaglandin metabolites do not necessarily reflect levels produced by vessels or platelets in the circulation. Indeed, Dr Fitzgerald's own work shows that orally administered aspirin inhibits the formation of thromboxane by clotting blood ex vivo (which is driven by platelets) much more readily than it reduces the levels of urinary thromboxane metabolites. 5 The simplest explanation for such results is that TXM does not reflect formation of thromboxane by platelets under physiological conditions and rather, as our study shows, can originate from the kidney. 2 Fourth, we were pleased to note that the authors provide no counter arguments to our conclusions about the origin of urinary PGIM in humans. 2 Instead the authors suggest that reduced PGIM in the urine of vascular COX-2 (cyclooxygenase-2) knockout mice 13 supports their position. However, this does not prove that COX-2 drives prostacyclin in the circulation and is more simply explained as prostacyclin generation by vascular cells within the kidney, an organ where COX-2 expression is well characterized.
14,15 Indeed, as we 4, 10 and others have shown repeatedly, it is COX-1, not COX-2, that is generally expressed in systemic blood vessels; the kidney is an exception where COX-2 is expressed.
Finally, and most importantly, in direct contrast to before surgery where the patient we describe did have chronic renal failure which progressed to severe renal failure necessitating 4 hours of hemodialysis 3× per week and passing <500 mL/d urine, after the kidney transplant the patient had (1) normal renal function with estimated glomerular filtration of >70 mL/min, (2) was not in renal failure, and (3) had no signs of inflammation measured as both low plasma C-reactive protein (<5) and absence of cellular infiltration in renal biopsies taken at 3-month post-transplant.
In summary, after transplantation of a healthy kidney to an individual lacking in cPLA 2 α (cytosolic phospholipase A 2 ) and in the complete absence of any signs of renal inflammation or dysfunction, the levels of urinary PGIM and TXM fall within the normal range. The simplest explanation is that the kidney forms PGIM and TXM.
